Adagene gets NMPA IND clearance for ADG138
Adagene received NMPA clearance for the IND of ADG138, a double-masked HER2×CD3 T-cell engager, with a Phase 1 study in advanced solid tumors expected to start in China in Q4 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.